Zhaoke Ophthalmology Shrinks Loss in 2024

MT Newswires Live03-25 09:46

Zhaoke Ophthalmology (HKG:6622) shrank its attributable loss for the year 2024 to 237.5 million yuan from 385 million yuan in the year-ago period, a Monday filing with the Hong Kong bourse said.

Loss per share stood at 0.43 yuan, down from 0.71 yuan in the corresponding period last year.

The ophthalmic pharmaceutical company's revenue for the year increased to 69.3 million yuan from 18.8 million yuan a year prior, mainly due to a rise in licensing income.

The firm attributed the lower loss mainly to a milestone payment received under a product license agreement, significant sales growth in key ophthalmic drug products, and lower R&D expenses.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522048660?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-25 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522048660","market":"us","top_or_hot":-1,"title":"Zhaoke Ophthalmology Shrinks Loss in 2024","media":"MT Newswires Live","content":"<html><body><p> Zhaoke Ophthalmology (HKG:6622) shrank its attributable loss for the year 2024 to 237.5 million yuan from 385 million yuan in the year-ago period, a Monday filing with the Hong Kong bourse said.</p><p>Loss per share stood at 0.43 yuan, down from 0.71 yuan in the corresponding period last year.</p><p>The ophthalmic pharmaceutical company's revenue for the year increased to 69.3 million yuan from 18.8 million yuan a year prior, mainly due to a rise in licensing income.</p><p>The firm attributed the lower loss mainly to a milestone payment received under a product license agreement, significant sales growth in key ophthalmic drug products, and lower R&amp;D expenses.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhaoke Ophthalmology Shrinks Loss in 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhaoke Ophthalmology Shrinks Loss in 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-25 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Zhaoke Ophthalmology (HKG:6622) shrank its attributable loss for the year 2024 to 237.5 million yuan from 385 million yuan in the year-ago period, a Monday filing with the Hong Kong bourse said.</p><p>Loss per share stood at 0.43 yuan, down from 0.71 yuan in the corresponding period last year.</p><p>The ophthalmic pharmaceutical company's revenue for the year increased to 69.3 million yuan from 18.8 million yuan a year prior, mainly due to a rise in licensing income.</p><p>The firm attributed the lower loss mainly to a milestone payment received under a product license agreement, significant sales growth in key ophthalmic drug products, and lower R&amp;D expenses.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2522048660","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522048660","pubTimestamp":1742895976,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zhaoke Ophthalmology  shrank its attributable loss for the year 2024 to 237.5 million yuan from 385 million yuan in the year-ago period, a Monday filing with the Hong Kong bourse said.Loss per share stood at 0.43 yuan, down from 0.71 yuan in the corresponding period last year.The ophthalmic pharmaceutical company's revenue for the year increased to 69.3 million yuan from 18.8 million yuan a year prior, mainly due to a rise in licensing income.The firm attributed the lower loss mainly to a milestone payment received under a product license agreement, significant sales growth in key ophthalmic drug products, and lower R&D expenses.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1583":"高瓴概念","BK1587":"次新股","06622":"兆科眼科-B","BK1191":"制药"},"translate_title":"兆科眼科2024年亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":0.9},"content_text":"Zhaoke Ophthalmology (HKG:6622) shrank its attributable loss for the year 2024 to 237.5 million yuan from 385 million yuan in the year-ago period, a Monday filing with the Hong Kong bourse said.Loss per share stood at 0.43 yuan, down from 0.71 yuan in the corresponding period last year.The ophthalmic pharmaceutical company's revenue for the year increased to 69.3 million yuan from 18.8 million yuan a year prior, mainly due to a rise in licensing income.The firm attributed the lower loss mainly to a milestone payment received under a product license agreement, significant sales growth in key ophthalmic drug products, and lower R&D expenses.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522048660"}